Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.67 |
| ▸ | AR | P10275 | 6/20 | 0.65 |
| ▸ | PGR | P06401 | 5/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.58 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157184 | 1.00 | CYP19A1 (0.67) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL13216950 | 1.00 | CYP19A1 (0.67) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL7080880 | 1.00 | CYP19A1 (0.67) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL29008753 | 1.00 | CYP19A1 (0.67) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL14342104 | 1.00 | CYP19A1 (0.67) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL5974440 | 0.88 | CYP19A1 (0.51) | CYP19A1ARPGRNR3C2 | |
| SCHEMBL7618203 | 0.88 | CYP19A1 (0.51) | CYP19A1ARPGRNR3C2 | |
| SCHEMBL5973825 | 0.84 | CYP19A1 (0.62) | CYP19A1ARPGRNR3C2 | |
| SCHEMBL1656778 | 0.84 | CYP19A1 (0.62) | CYP19A1ARPGRNR3C2 | |
| SCHEMBL13809835 | 0.82 | CYP19A1 (0.60) | CYP19A1ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343806-B1 | METHYLENE STEROIDS AS NOVEL ANDROGENS | ORGANON NV (NL) | 2008-05-28 | — | — | EP | disclosed |
| US-6949531-B2 | 14 β, 16, 17-methylene steroids as novel androgens | AKZO NOBEL N.V. (NL) | 2005-09-27 | — | — | US | disclosed |
| US-20040030165-A1 | 14 Beta, 16, 17-methylene steroids as novel androgens | MERCK SHARP & DOHME B.V. (NL) | 2004-02-12 | — | — | US | disclosed |
| EP-1343806-A1 | METHYLENE STEROIDS AS NOVEL ANDROGENS | Akzo Nobel N.V. (NL) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048171-A1 | METHYLENE STEROIDS AS NOVEL ANDROGENS | AKZO NOBEL N.V. (NL) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030165-A1 | 14 Beta, 16, 17-methylene steroids as novel androgens | CYP17A1, HSD17B7, AR | CYP19A1 21/4885AR 3/4885PGR 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.